The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years at the company.
It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease.
AI chip suppliers are enjoying a spending boom from ‘hyperscalers,’ which in turn use the technology to boost sales and profits.
The chances of another rate cut this year by the Bank of England has diminished after data showed an acceleration in the pace of Britain’s inflation last month.
Target’s stock set to suffer worst day in more than two years after profit, revenue, comparable sales and the outlook were all below expectations.
Mortgage applications rose 1.7% in the last week, the Mortgage Bankers Association said.
The S&P 500 has bounced from its drop last week, a decline that had eroded its U.S. election bump without knocking the index off course toward a potentially big 2024 gain.
Hedge funds are picking up stocks in nuclear power producers in seeking to capitalize on the artificial intelligence boom, new analysis from Goldman Sachs shows
